A Lesson to Learn o...
Health Care: Drugs
NovaBay Pharmaceuticals Inc. (NBY: AMEX)
$1.34 0.01 | 0.75%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.34 |
| 52 Week High | 1.76 |
| 52 Week Low | 1.05 |
| Avg. Daily Vol. (Mil) | 0.19 |
| Beta (3 year) | 1.38 |
| Share Related Items | |
| Mkt Cap (Mil) | 50.02 |
| Shares Out (Mil) | 37.33 |
| Float (Mil) | 30.43 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.70 |
| Current Ratio | 5.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 7.53 |
| Price/Book | 4.84 |
| Price/Cash Flow | -4.70 |
| Per Share Data | |
| Earnings | -0.27 |
| Sales | 0.18 |
| Book Value | 0.28 |
| Cash Flow | -0.29 |
| Business Summary | |
|---|---|
| NovaBay Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market. | |
| General Information | |
| 5980 Horton street
Suite 550 Emeryville, CA 94608 |
|
| www.novabaypharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 26 | |
| CEO: Dr. Ramin Najafi,PhD | |
| Short Interest | |
| Current Month (Mil) | 1.42 |
| Previous Month (Mil) | 1.49 |
| Short Interest Ratio (Days) | 11.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -71.60 |
| Return on Investments | -106.00 |
| Profitability | |
| Gross Margin | 99.70 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with NBY
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Contributor10 Biotech Stocks Expected ...
- UserRAPTOR SPRTD-0705091614
- Usermartynorm Portfolio 1
Latest NBY Headlines from TheStreet
- NovaBay Supports Legislation To Attack Antibiotic Resistance 06.17.13 | 08:06 am
- NovaBay Pharmaceuticals Mid-Year Clinical Update 06.11.13 | 08:06 am
- NovaBay Pharmaceuticals And Virbac Enter Into A Collaboration And License Agreement For Animal Health 05.28.13 | 03:05 am
- NovaBay Pharmaceuticals Reports First Quarter Financial Results And Clinical And Business Update 05.02.13 | 08:05 am
- NovaBay Global Ophthalmology Study Enrolls First Patients In Brazil 04.08.13 | 07:04 am
- NovaBay CEO Interviewed On RedChip Money Report On Fox Business News 03.18.13 | 06:03 am
- NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results And 2013 Clinical And Business Update 03.14.13 | 06:03 am
- NovaBay Pharmaceuticals To Present At The 25th Annual ROTH Conference 03.12.13 | 07:03 am
- NovaBay Names Keith Bley As Senior Vice President Of Product Development 03.11.13 | 07:03 am
- NovaBay Receives Unique Globally Recognized International Nonproprietary Name Auriclosene For NVC-422 02.20.13 | 07:02 am
Press Releases for NBY
Partner Headlines for NBY
- NovaBay: Working On An Effective Treatment For Viral Conjunctivitis - Seeking Alpha 04.13.13 | 08:04 am
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Diverse Pipeline And Multiple Catalysts Point To Buying Opportunity In NovaBay Pharmaceuticals - Seeking Alpha 09.06.12 | 09:09 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Novabay Announces Neutrophase Available in Spray Pump - Benzinga 08.27.12 | 09:08 am
- NovaBay Pharmaceuticals: A Potential Bargain With Catalysts Pending - Seeking Alpha 06.13.12 | 09:06 am
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- NovaBay Pharmaceuticals: Key Deal Marks A Year Of Swift Progression - Seeking Alpha 01.10.12 | 08:01 am
